Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
6
×
eli lilly
6
×
life sciences
national blog main
boston top stories
clinical trials
indiana blog main
indiana top stories
national top stories
san francisco blog main
san francisco top stories
fda
raleigh-durham blog main
raleigh-durham top stories
teva pharmaceutical
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fremanezumab
migraine research foundation
national
new york blog main
new york top stories
novartis
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
avapritinib
blueprint medicines
boston
calcitonin gene-related peptide
cancer
What
approval
6
×
drug
6
×
fda
new
medicines
migraine
won
blueprint
cancer
class
companies
decades
ret
acute
address
addresses
amgen
approves
arguments
big
bio
biogen’s
biopharmaceutical
candidate
candidates
carries
causes
certain
commercialized
competitors
condition
convo
currently
designed
developed
drugs
earlier
eli
failures
friday
Language
unset
Current search:
drug
×
approval
×
" eli lilly "
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines